# Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/abemaciclib-plus-trastuzumab-with-or-without-fulvestrant-versus-trastuzumab-plus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Sara M. Tolaney,Andrew Wardley,Stefania Zambelli,John Hilton,Tiffany A. Troso-Sandoval,Francesco Ricci,Seock‐Ah Im,Sung‐Bae Kim,Stephen Johnston,Arlene Chan,Shom Goel,Kristen Catron,Sonya C. Chapman,Gregory L. Price,Zhengyu Yang,M. Corona Gainford,Fabrice André |
| Citations | 261 |
| DOI | 10.1016/s1470-2045(20)30112-1 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3020482066 |
| PMID | 32353342 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Zhengyu Yang](https://scholariq.org/researchers/zhengyu-yang/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Paper topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.